Thanks very much, BDZ...

""Both! I can see Vascepa and Apabetalone being used together down the road. But I'm sure some physicians will prescribe/advise to use an either/or approach.""

Not being a cardiologist - or even having visited one - I'm just assuming there will be a fair amount of either/or, as long as it is perceived that there's an overlap of benefits.

"""Please expand on how the EVAPORATE trial will clarify the above. Are you simply suggesting that showing plaque reduction in EVAPORATE will clarify one of the ways that Vascepa is cardioprotective?"""

Hopefully, of course. But also that it will somewhat further differentiate Vascepa from Apabetalone, at least until Apabelaone catches up.

""Correct. MACE reduction in REDUCE-IT was more or less indepedent of triglyceride reduction, baseline triglyceride level and achieved triglyeride level. So REDUCE-IT wasn't so much a trial that proved plasma triglyerides to be a cardio risk factor""

OK, I guess that's why the earlier Phase 3 for Vascepa - showing lower TG's - generated a yawn from the FDA. Perhaps the goalposts shifted during that trial because people changed from thinking of TG's as the villains to thinking of them as sort of ugly collateral damage? Pure supposition on my part, as I'm getting way outside my actual understanding of any of this.

"""It is an extreme oversimplification to state the plasma TG are a biomarker for inflammation."""

OK, it's an oversimplfication.... but is it correct to any significant degree?